Department of Trauma, Hand and Reconstructive Surgery, Hospital of the Johann Wolfgang, Goethe-University, Frankfurt, Germany.
J Trauma Acute Care Surg. 2012 Oct;73(4):838-42. doi: 10.1097/TA.0b013e31825ac394.
Clara cell protein 16 (CC16) has recently gained acceptance as a blood biomarker for detecting direct and indirect lung injury. Although the early elevation of CC16 serum levels has been shown to correlate with pulmonary damage in patients with multiple injuries, the subsequent time course of CC16 serum levels has not been investigated in these patients.
Fifty-eight patients with multiple injuries, 32 with severe thoracic injury, and 12 healthy volunteers were enrolled in this study. CC16 serum levels were measured at the time they were admitted to the trauma ward "time 0" and subsequently until day 14 using the enzyme-linked immunosorbent assay technique. The correlation between CC16 serum levels and severe lung injury, onset of nosocomial pneumonia, acute respiratory distress syndrome or acute lung injury, and organ failure was measured. In addition, areas under the receiver operating characteristic curve were calculated (p < 0.05 = significant).
In patients with lung injury, initial "time 0" median CC16 values were significantly elevated (11.2 ng/mL) compared with patients without severe thoracic injury (6.9 ng/mL) and controls (6.3 ng/mL). The observed elevation in serum CC16 declined to control values within 12 to 24 hours after trauma unless patients secondarily developed pneumonia. In the latter patients, median CC16 serum levels were significantly elevated (14.5 ng/mL) at the onset of pneumonia compared with their levels (7.3 ng/mL) 1 day before. In contrast, no secondary elevation in CC16 serum levels was observed in patients without severe lung injury within the same 24-hour period. The area under the receiver operating characteristic curve for serum CC16 and pneumonia was 0.79 (0.62-0.97; p = 0.0011).
Our results confirm the previously described association between initial elevation in CC16 serum levels and severe thoracic injury in patients with multiple injuries. In addition, we found that the initial elevation in CC16 serum levels declines to control values within the first day after trauma and that a secondary elevation indicates respiratory complications.
Diagnostic study, level II.
克拉拉细胞蛋白 16(CC16)最近被接受为一种检测直接和间接肺损伤的血液生物标志物。虽然已经表明,多发性损伤患者的 CC16 血清水平早期升高与肺损伤相关,但这些患者的 CC16 血清水平随后的时间过程尚未被研究。
本研究纳入了 58 例多发性损伤患者,其中 32 例伴有严重胸部损伤,12 例健康志愿者。使用酶联免疫吸附试验技术,在患者入院创伤病房时(“时间 0”)测量 CC16 血清水平,并随后测量至第 14 天。测量 CC16 血清水平与严重肺损伤、医院获得性肺炎、急性呼吸窘迫综合征或急性肺损伤以及器官衰竭之间的相关性。此外,计算了受试者工作特征曲线下的面积(p<0.05=有统计学意义)。
在有肺损伤的患者中,初始“时间 0”的中位数 CC16 值明显升高(11.2ng/mL),与无严重胸部损伤的患者(6.9ng/mL)和对照组(6.3ng/mL)相比。在创伤后 12 至 24 小时内,观察到的血清 CC16 升高降至对照值,除非患者继发肺炎。在后一组患者中,肺炎发作时的中位数 CC16 血清水平明显升高(14.5ng/mL),而前一天的水平为(7.3ng/mL)。相比之下,在同一 24 小时内,无严重肺损伤的患者的 CC16 血清水平没有二次升高。血清 CC16 和肺炎的受试者工作特征曲线下面积为 0.79(0.62-0.97;p=0.0011)。
我们的结果证实了之前描述的多发性损伤患者中 CC16 血清水平的初始升高与严重胸部损伤之间的关联。此外,我们发现 CC16 血清水平的初始升高在创伤后第一天内降至对照值,而二次升高表明存在呼吸并发症。
诊断研究,II 级。